Movatterモバイル変換

Cefmenoksim

С Википедије, слободне енциклопедије

Cefmenoksim
Klinički podaci

Prodajno ime	Bestcall, Cefmax, Tacef
Drugs.com	Monografija
Način primene	Intramaskularno
Farmakokinetički podaci
Poluvreme eliminacije	1 h

Identifikatori
CAS broj	65085-01-0^Y
ATC kod	J01DD05 (WHO)
PubChem	CID9570757
DrugBank	DB00267^Y
ChemSpider	7845223^Y
ChEBI	CHEBI:55490^Y
ChEMBL	CHEMBL1201224^Y
Hemijski podaci
Formula	C₁₆H₁₇N₉O₅S₃
Molarna masa	511,558
SMILES [H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
InChI InChI=1S/C16H17N9O5S3/c1-24-16(20-22-23-24)33-4-6-3-31-13-9(12(27)25(13)10(6)14(28)29)19-11(26)8(21-30-2)7-5-32-15(17)18-7/h5,9,13H,3-4H2,1-2H3,(H2,17,18)(H,19,26)(H,28,29)/b21-8-/t9-,13-/m1/s1^Y Key:HJJDBAOLQAWBMH-YCRCPZNHSA-N^Y

Cefmenoksim jeorgansko jedinjenje, koje sadrži 16atoma ugljenika i imamolekulsku masu od 511,558Da.^[1]^[2]^[3]^[4]^[5]^[6]

Osobine

[уреди |уреди извор]

Osobina	Vrednost
Broj akceptora vodonika	13
Broj donora vodonika	3
Broj rotacionih veza	8
Particioni koeficijent^[7] (ALogP)	-0,7
Rastvorljivost^[8] (logS, log(mol/L))	-3,8
Polarna površina^[9] (PSA,Å²)	269,6

Reference

[уреди |уреди извор]

^Yokota N, Koguchi M, Suzuki Y, Fukayama S, Ishihara R, Deguchi K, Oda S, Tanaka S, Nakane Y, Fukumoto T: [Antibacterial activities of cefmenoxime against recent fresh clinical isolates from patients in sinusitis] Jpn J Antibiot. 1995 May;48(5):602-9.PMID 7637194
^Paladino JA, Fell RE: Pharmacoeconomic analysis of cefmenoxime dual individualization in the treatment of nosocomial pneumonia. Ann Pharmacother. 1994 Mar;28(3):384-9.PMID 8193431
^Duncker GI, Reich U, Krausse R: Cefmenoxime in corneal organ culture. Ophthalmologica. 1994;208(5):262-6.PMID 7816419
^Tsuchiya K, Kondo M, Kida M, Nakao M, Iwahi T, Nishi T, Noji Y, Takeuchi M, Nozaki Y: Cefmenoxime (SCE-1365), a novel broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities. Antimicrob Agents Chemother. 1981 Jan;19(1):56-65.PMID 6941742
^Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011).„DrugBank 3.0: a comprehensive resource for omics research on drugs”.Nucleic Acids Res.39 (Database issue): D1035—41.PMC 3013709 .PMID 21059682.doi:10.1093/nar/gkq1126.
^David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008).„DrugBank: a knowledgebase for drugs, drug actions and drug targets”.Nucleic acids research.36 (Database issue): D901—6.PMC 2238889 .PMID 18048412.doi:10.1093/nar/gkm958.
^Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998).„Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”.J. Phys. Chem. A.102: 3762—3772.doi:10.1021/jp980230o.
^Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001).„Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”.Chem Inf. Comput. Sci.41: 1488—1493.PMID 11749573.doi:10.1021/ci000392t.
^Ertl P.; Rohde B.; Selzer P. (2000).„Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”.J. Med. Chem.43: 3714—3717.PMID 11020286.doi:10.1021/jm000942e.